Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 53Ovarian Neoplasms 4Prostatic Neoplasms 3Neoplasms 3Inflammatory Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Solid Tumor 2Rectal Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia 1Malignant Solid Neoplasm 1Lung Neoplasms 1Locally Advanced Breast Cancer 1Her2-Positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

Everolimus 5Topotecan 2Etoposide 2Cisplatin 2Bevacizumab 2veliparib 1pralsetinib 1pertuzumab 1pembrolizumab 1pasireotide 1lenvatinib 1carfilzomib 1cabozantinib 1berzosertib 1Temozolomide 1Sunitinib 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Podophyllotoxin 1Platinum 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Neuroendocrine × pertuzumab × Clear all
NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
43 enrolled 9 charts
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡